Virax Biolabs

Update in progress

VRAX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Virax Biolabs Group Limited is a biotechnology company that distributes in vitro diagnostic test kits for viral disease prevention, detection, and risk management. Its ViraxClear line covers respiratory, pregnancy, infectious diseases, STI, drugs of abuse, oncology, cardiac, and women’s health kits; ViraxVet offers small animal veterinary tests; ViraxImmune provides a T cell assay and wellness app. The company also offers antibody engineering, peptides, sequencing, vaccine testing, lab services, and kits. It engages in R&D and procurement, warehousing, product development, and staffing services. Serving research organizations, laboratories, hospitals, distributors, and other institutions, it operates in the UK, US, and China. Formerly Virax Biolabs (Cayman) Limited, renamed in 2021. Founded 2013, headquartered in Lanarkshire, United Kingdom.

Company score

Sentiment: 0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.12; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive